BHC Logo

Bausch Health Companies Inc. (BHC) 

NYSE
Market Cap
$3.03B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
344 of 775
Rank in Industry
16 of 47

Largest Insider Buys in Sector

BHC Stock Price History Chart

BHC Stock Performance

About Bausch Health Companies Inc.

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The …

Insider Activity of Bausch Health Companies Inc.

Over the last 12 months, insiders at Bausch Health Companies Inc. have bought $0 and sold $146,519 worth of Bausch Health Companies Inc. stock.

On average, over the past 5 years, insiders at Bausch Health Companies Inc. have bought $68.53M and sold $10.06M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 60,000 shares for transaction amount of $1.45M was made by Miller Steven D (director) on 2021‑11‑30.

List of Insider Buy and Sell Transactions, Bausch Health Companies Inc.

2024-09-06SaleEVP, General Counsel
13,370
0.0036%
$6.21$83,028+31.56%
2024-03-04SaleEVP, General Counsel
6,313
0.0018%
$9.80$61,867-17.12%
2023-12-05SaleEVP, General Counsel
220
<0.0001%
$7.38$1,624+12.79%
2023-11-06SaleEVP, General Counsel
43
<0.0001%
$7.61$327+4.86%
2023-09-06SaleEVP, General Counsel
6,685
0.0018%
$8.28$55,352-8.67%
2023-03-06SaleEVP, General Counsel
495
0.0001%
$9.17$4,539-10.20%
2023-03-03SaleEVP, General Counsel
780
0.0002%
$9.34$7,285-14.30%
2023-02-28SaleEVP, General Counsel
292
<0.0001%
$9.32$2,721-15.31%
2022-04-14SaleU.S. President-Pharma Business
1,595
0.0004%
$22.19$35,393-65.94%
2022-03-15SaleU.S. President-Pharma Business
4,846
0.0014%
$22.20$107,581-65.00%
2022-03-08SalePres&Co-Head Bausch&Lomb/Int'l
3,889
0.0011%
$21.76$84,625-64.35%
2022-03-02SalePres&Co-Head Bausch&Lomb/Int'l
11,077
0.003%
$23.37$258,869-68.14%
2022-03-02SaleU.S. President-Pharma Business
1,595
0.0004%
$23.37$37,275-68.14%
2022-03-01SalePres&Co-Head Bausch&Lomb/Int'l
6,338
0.0018%
$23.82$150,971-67.14%
2022-02-15SaleU.S. President-Pharma Business
3,251
0.0009%
$25.02$81,340-69.84%
2022-01-18SaleU.S. President-Pharma Business
3,251
0.0009%
$26.63$86,574-70.45%
2021-11-30Purchasedirector
60,000
0.017%
$24.23$1.45M-60.82%
2021-08-05Purchasedirector
2,800
0.0008%
$25.94$72,632-6.04%
2021-08-04Purchasedirector
20,000
0.0056%
$25.01$500,246-2.62%
2021-06-11SaleEVP & Chief Financial Officer
34,000
0.0094%
$31.68$1.08M-17.77%

Insider Historical Profitability

11.48%
Paulson John
25839035
7.0252%
$8.2352+31.4%
ValueAct Holdings, L.P.director
17931594
4.8753%
$8.23193+19.98%
Pearson J. MichaelChief Executive Officer
1514664
0.4118%
$8.2321+21.28%
Morfit G MasonSee Remarks
1352941
0.3678%
$8.2310+30.3%
UBBEN JEFFREY Wdirector
1059793
0.2881%
$8.2331+44.4%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
ICAHN CARL C$368.39M9.6234.72M0%+$03.29
GoldenTree Asset Management$293.31M7.6627.64M0%+$025.67
Paulson & Co.$280.52M7.3226.44M0%+$019.38
Franklin Templeton Investments$168.18M4.3915.85M+0.32%+$528,788.170.05
National Bank Of Canada Fi$107.75M4.3415.66M+0.07%+$80,874.830.18
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.